SIREN : 435128988
IDI PHARMA is a French company founded 25 years ago, specialized in the sector Ingénierie, études techniques. Based in ROEZE-SUR-SARTHE (72210), this company of category PME shows in 2025 a revenue of 1.7 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-05-02
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicator | 2025 | 2024 | 2023 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1 741 634 € | 1 426 779 € | 1 737 427 € | N/C | N/C | N/C | 2 535 716 € | 1 440 274 € |
| Net income | 83 993 € | 68 491 € | 194 730 € | 58 059 € | -24 947 € | 133 212 € | 226 364 € | -55 868 € |
| EBITDA | 121 846 € | 102 051 € | 256 254 € | N/C | N/C | N/C | 137 001 € | 45 885 € |
| Net margin | 4.8% | 4.8% | 11.2% | N/C | N/C | N/C | 8.9% | -3.9% |
In 2025, IDI PHARMA achieves revenue of 1.7 M€. Revenue is growing positively over 8 years (CAGR: +2.4%). Vs 2024, growth of +22% (1.4 M€ -> 1.7 M€). After deducting consumption (562 k€), gross margin stands at 1.2 M€, i.e. a rate of 68%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches 122 k€, representing 7.0% of revenue. The operating margin remains fragile, requiring cost vigilance. Ultimately, net income (= EBIT +/- financial result +/- exceptional - corporate tax) amounts to 84 k€, i.e. 4.8% of revenue. This profit can be retained or distributed to shareholders.
1 741 634 €
1 179 352 €
121 846 €
106 561 €
83 993 €
7.0%
The debt ratio (= Financial debt / Equity x 100) stands at 35%. Debt remains under control: the company retains capacity to raise new debt if needed. Financial autonomy (= Equity / Total assets x 100) reaches 41%. This high autonomy means the company finances most of its assets through equity, a sign of strength. Debt repayment capacity (= Financial debt / Cash flow) indicates it would take 1.6 years of cash flow to repay all financial debt. This short period demonstrates excellent debt sustainability. Cash flow represents 5.7% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment. Satisfactory level allowing partial financing of growth.
35.2%
40.65%
5.71%
1.554
15.8%
In 2025, the debt ratio of IDI PHARMA (35.20) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.
In 2025, the financial autonomy of IDI PHARMA (40.6%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.
In 2025, the repayment capacity of IDI PHARMA (1.55) ranks above the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A reduction effort could improve financial strength.
The liquidity ratio (= Current assets / Current liabilities) stands at 312.02. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months. The interest coverage ratio (= EBIT / Interest expenses) is 1.6x. Coverage is limited: any activity downturn would jeopardize interest payments.
312.025
1.602
In 2025, the liquidity ratio of IDI PHARMA (312.02) ranks above the median of the sector. This ratio measures the ability to cover short-term debt with current assets. This comfortable position offers an appreciable safety margin.
In 2025, the interest coverage of IDI PHARMA (1.6x) ranks above the median of the sector. This ratio indicates how many times operating income covers interest expenses. This comfortable position offers an appreciable safety margin.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 83 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 45 days. The gap of 38 days means the company finances its customers for over a month before being paid relative to supplier payments. This weighs on cash flow. Inventory turnover is 57 days (= Average inventory / Cost of goods x 360). Overall, WCR represents 99 days of revenue, i.e. 481 k€ to permanently finance.
480 795 €
83 j
45 j
57 j
99 j
Indicative estimate only : the number of comparable transactions in this sector is limited (34 transactions). This range of 98 543€ to 439 370€ is provided for information purposes only and requires in-depth analysis to be confirmed.
This estimate is based on the analysis of 34 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Compare IDI PHARMA with other companies in the same sector:
Voir toutes les statistiques du secteur Ingénierie, études techniques
The revenue of IDI PHARMA in 2025 is 1.7 M€.
Yes, IDI PHARMA generated a net profit of 84 k€ in 2025.
The headquarters of IDI PHARMA is located in ROEZE-SUR-SARTHE (72210), in the department Sarthe.
The tax return of IDI PHARMA is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
IDI PHARMA operates in the sector Ingénierie, études techniques (NAF code 71.12B). See the 'Sector positioning' section above to compare the company with its competitors.